{
  "docId": "019de074-c46c-7261-862e-11078609bbd6",
  "docSlug": "94ed059236b735624310519badaf5152",
  "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 32 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 32,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "thesis_headline",
  "function": "establish_context",
  "density": "sparse",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-c46c-7261-862e-11078609bbd6/9",
  "deckHref": "/decks/019de074-c46c-7261-862e-11078609bbd6",
  "deckJsonHref": "/decks/019de074-c46c-7261-862e-11078609bbd6.json",
  "deckAnchorHref": "/decks/019de074-c46c-7261-862e-11078609bbd6#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.085,
        "w": 0.864,
        "x": 0.068,
        "y": 0.588
      },
      "kind": "paragraph",
      "text": "For symptomatic neurogenic orthostatic hypotension (nOH) in multiple system atrophy (MSA) patients",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "027215cd-fbce-40b0-b5b5-78f6cb3502ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.042,
        "w": 0.833,
        "x": 0.068,
        "y": 0.475
      },
      "kind": "paragraph",
      "text": "Investigational once-daily norepinephrine reuptake inhibitor",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c1a6917-9ab5-4e94-bef1-7e547c1185c3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.085,
        "w": 0.371,
        "x": 0.068,
        "y": 0.295
      },
      "kind": "title",
      "text": "Ampreloxetine",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6f5c6f2-e9a6-46f0-b7cd-4b6172fcb889",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 9,
      "beatId": "d132e7bb-1e61-495f-bb4f-ef4446fa6467",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The presentation highlights the need for new treatments for MSA symptoms and the benefits of Ampreloxetine.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 11,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "7f6b888f-01a2-48da-9e93-f1fbf3089b2a",
      "evidence": "The presentation highlights the benefits of Ampreloxetine in addressing MSA symptoms.",
      "position": 0,
      "objective": "What are the consequences of not treating MSA symptoms effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}